Ahammune Biosciences Raises $5M to Fast-Track Drug Development for Vitiligo

SciFocus/Sept 26, 2024 -- Pioneering biotech startup Ahammune Biosciences Pvt. Ltd. has secured $5M in Series A funding to accelerate its breakthrough treatments for vitiligo and other chronic skin diseases. This funding marks a critical step in their mission to revolutionize dermatological care.

"Our novel drug candidate not only halts the spread of vitiligo but stimulates repigmentation, addressing a huge unmet need in treatment options," said Dr. Parul Ganju, cofounder and CEO of Ahammune Biosciences.

Key Highlights:

- Funding Led by pi Ventures: Backed by Capital2B, Colossa Ventures, Bipin Agarwal, Unicornus Maximus, and Ideaspring Capital.

- Purpose of Funds: Supports Phase 2 clinical trials for Ahammune's vitiligo drug, expands patent portfolio, and boosts R&D for other skin diseases.

- Innovation in Dermatology: Ahammune's small molecule drug for vitiligo avoids general immunosuppression, a first-in-class mechanism.

- Future Pipeline: The company is also developing a second drug to treat eczema, another widespread skin disorder.

- Growing Patent Portfolio: Filed 20 patent applications, with seven already granted globally.

Ahammune's innovative approach could set a new standard in skin disease treatments, with a focus on efficacy and safety.

Website: https://www.ahammune.com/

If you're enjoying this content, sign up to SciFocus daily newsletter by Biopatrika for all the biggest stories in Science, healthcare, STEM, startups, and how we're advocating to "Bring Science to Society." #SciFocus #Biopatrika

For partnership or advertisement opportunities, feel free to contact us here or visit www.biopatrika.com.

Career Opportunities: Biopatrika Career Hub https://www.dhirubhai.net/groups/13946324/

Follow Virender Singh and Biopatrika on LinkedIn.